Author(s): No authors listed
Abstract Share this page
Abstract The FDA has approved the marketing of an extended-release formulation of trazodone (Oleptro--Angelini Labopharm) for treatment of major depressive disorder in adults. Immediate-release trazodone has been available for treatment of depression for many years, but is used mostly in low doses for its sedating effects.
This article was published in Med Lett Drugs Ther
and referenced in Journal of Biomedical Engineering and Medical Devices